Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Niven Mehra

Showing results (121-130 of 161) with videos related to

Pageof 17
Sort By:
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
Nature Communications|November 22, 2019
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impactLisanne F van Dessel, Job van Riet, Minke Smits, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
Cancer Gene Therapy|June 17, 2021
Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer modelsArjanneke F van de Merbel, Geertje van der Horst, Maaike H van der Mark, et al.
Journal for Immunotherapy of Cancer|October 8, 2021
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicineElisa Baldelli, K Alex Hodge, Guido Bellezza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor TypesHanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2024
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer MicroenvironmentMaksim A Chelushkin, Jeroen van Dorp, Sandra van Wilpe, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2025
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trialChantal F Stockem, Jeroen van Dorp, Nick van Dijk, et al.
Pageof 17

Showing results (121-130 of 161) with videos related to

Sort By:
Pageof 17
European Urology Oncology|July 17, 2019
Early Post-treatment Prostate-specific Antigen at 4 Weeks and Abiraterone and Enzalutamide Treatment for Advanced Prostate Cancer: An International Collaborative AnalysisPasquale Rescigno, David Dolling, Vincenza Conteduca, et al.
Cancers|January 8, 2023
PSMA-RLT in Patients with Metastatic Hormone-Sensitive Prostate Cancer: A Retrospective StudyAmina Banda, Bastiaan M Privé, Youssra Allach, et al.
Nature Communications|November 22, 2019
The genomic landscape of metastatic castration-resistant prostate cancers reveals multiple distinct genotypes with potential clinical impactLisanne F van Dessel, Job van Riet, Minke Smits, et al.
Journal for Immunotherapy of Cancer|November 16, 2019
Blood-derived dendritic cell vaccinations induce immune responses that correlate with clinical outcome in patients with chemo-naive castration-resistant prostate cancerHarm Westdorp, Jeroen H A Creemers, Inge M van Oort, et al.
Cancer Gene Therapy|June 17, 2021
Reovirus mutant jin-3 exhibits lytic and immune-stimulatory effects in preclinical human prostate cancer modelsArjanneke F van de Merbel, Geertje van der Horst, Maaike H van der Mark, et al.
Journal for Immunotherapy of Cancer|October 8, 2021
PD-L1 quantification across tumor types using the reverse phase protein microarray: implications for precision medicineElisa Baldelli, K Alex Hodge, Guido Bellezza, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 3, 2021
Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor TypesHanneke van der Wijngaart, Louisa R Hoes, J Maxime van Berge Henegouwen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 24, 2024
Platinum-Based Chemotherapy Induces Opposing Effects on Immunotherapy Response-Related Spatial and Stromal Biomarkers in the Bladder Cancer MicroenvironmentMaksim A Chelushkin, Jeroen van Dorp, Sandra van Wilpe, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
European Journal of Cancer (Oxford, England : 1990)|September 11, 2025
Final clinical analysis of pre-operative ipilimumab and nivolumab in locally advanced urothelial cancer and exploration of tumor-draining lymph node composition: The NABUCCO trialChantal F Stockem, Jeroen van Dorp, Nick van Dijk, et al.
Pageof 17